Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00055549
Status:
COMPLETED
Last Update Posted:
2017-07-02
First Post:
2003-03-05
Brief Title:
Dextromethorphan to Treat Patients With Voice Spasms
Sponsor:
National Institute of Neurological Disorders and Stroke NINDS
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
The Effects of an NMDA-Receptor Antagonist in Idiopathic Voice Disorders
Status:
COMPLETED
Status Verified Date:
2009-11-13
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will examine how dextromethorphan a drug that alters reflexes of the larynx voice box might change voice symptoms in people with voice disorders due to uncontrolled laryngeal muscle spasms These include abductor spasmodic dysphonia breathy voice breaks adductor spasmodic dysphonia vowel breaks muscular tension dysphonia tight strained voice and vocal tremor tremulous voice Dextromethorphan-one of a group of drugs called NMDA antagonists-has been used for years in over-the-counter cough suppressant medicines In animal studies the drug has blocked one of the reflexes in the larynx that may be associated with spasms in the laryngeal muscles This study will compare the effects of dextromethorphan lorazepam a valium-type drug and a placebo inactive substance in patients with the four types of voice disorders described above
Patients with spasmodic dysphonia muscular tension dysphonia and vocal tremor may be eligible for this study Individuals who smoke or use tobacco who have vocal nodules or polyps or who have a history of airway obstruction may not participate Candidates will be screened with a medical history and physical examination a questionnaire voice recording repeating sentences into a microphone and nasolaryngoscopy examination of the larynx with a tube advanced through the nose For the nasolaryngoscopy the inside of the nose is sprayed with a decongestant to open the nasal passages and possibly a local anesthetic A small flexible tube called a nasolaryngoscope is passed through the nose to look at the larynx during speech and other tasks such as singing whistling and prolonged vowels
Participants will be admitted to the NIH Clinical Center for each of three visits which will last from the afternoon of one day to late afternoon of the following day At each visit patients will complete a questionnaire baseline speech recording and a test for sedation level They will take three pills-either dextromethorphan lorazepam or placebo-one every 6 hours Vital signs will be checked every 6 hours and the level of sedation during waking hours will be monitored One to three hours after taking the third pill speech recording questionnaire and test of sedation will be repeated to check for possible voice changes Patients will be given a different pill at each visit
Patients with spasmodic dysphonia muscular tension dysphonia and vocal tremor may be eligible for this study Individuals who smoke or use tobacco who have vocal nodules or polyps or who have a history of airway obstruction may not participate Candidates will be screened with a medical history and physical examination a questionnaire voice recording repeating sentences into a microphone and nasolaryngoscopy examination of the larynx with a tube advanced through the nose For the nasolaryngoscopy the inside of the nose is sprayed with a decongestant to open the nasal passages and possibly a local anesthetic A small flexible tube called a nasolaryngoscope is passed through the nose to look at the larynx during speech and other tasks such as singing whistling and prolonged vowels
Participants will be admitted to the NIH Clinical Center for each of three visits which will last from the afternoon of one day to late afternoon of the following day At each visit patients will complete a questionnaire baseline speech recording and a test for sedation level They will take three pills-either dextromethorphan lorazepam or placebo-one every 6 hours Vital signs will be checked every 6 hours and the level of sedation during waking hours will be monitored One to three hours after taking the third pill speech recording questionnaire and test of sedation will be repeated to check for possible voice changes Patients will be given a different pill at each visit
Detailed Description:
Studies of spasmodic dysphonia SD have increasingly pointed to the possibility of a central sensori-motor control disorder Sensori-motor processing has been found abnormal in both adductor and abductor spasmodic dysphonia based on reflex conditioning studies These studies demonstrated an increased frequency of R2 muscle responses during rapid paired presentation of electrical stimuli to the superior laryngeal nerve in spasmodic dysphonia Thus uncontrolled R2 responses were hypothesized to be the basis for the uncontrolled muscle bursts in these patients Selective suppression of late R2 laryngeal adductor responses by N-methyl-D-Aspartate NMDA blockade in cats was demonstrated by Ambalavanar etal In particular dextromethorphan reduced the frequency of R2 responses from 95 to 25 P 0015 Dextromethorphan is a widely used antitussive agent that has been in use for over 30 years In a double-blind randomized crossover design 3 groups of patients will receive be randomly assigned to one of 6 order cohorts They will then receive either dextromethorphan at a 8 mgkgd dose divided in a Q6 hour dosing schedule with only 3 doses administered PO every 6 hours for 3 dosages 04 mgkgd of lorazepam PO every 6 hours for 3 dosages or a placebo administrated in the same way during Phase A After a minimum of a 1-week washout interval the patients will be given either the other medication or placebo during Phase B and then the remaining medication or placebo during Phase C
Our hypothesis is that dextromethorphan an NMDA receptor blocker will reduce voice breaks in spasmodic dysphonia to a greater degree than lorazepam which has similar sedating side effects but does not affect NMDA receptors with a different mechanism On the other hand patients with other idiopathic voice disorders muscular tension dysphonia and vocal tremor are hypothesized not to have a similar benefit from dextromethorphan During the double-blind randomized cross-over study three groups will be included 10 patients with adductor or abductor spasmodic dysphonia 10 with muscular tension dysphonia and 10 with vocal tremor The results will determine if dextromethorphan has potential as a treatment option for patients with adductor or abductor SD
Our hypothesis is that dextromethorphan an NMDA receptor blocker will reduce voice breaks in spasmodic dysphonia to a greater degree than lorazepam which has similar sedating side effects but does not affect NMDA receptors with a different mechanism On the other hand patients with other idiopathic voice disorders muscular tension dysphonia and vocal tremor are hypothesized not to have a similar benefit from dextromethorphan During the double-blind randomized cross-over study three groups will be included 10 patients with adductor or abductor spasmodic dysphonia 10 with muscular tension dysphonia and 10 with vocal tremor The results will determine if dextromethorphan has potential as a treatment option for patients with adductor or abductor SD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 03-N-0119 | None | None | None |